Lactosylceramide recruits PKCα/ε and phospholipase A2 to stimulate PECAM-1 expression in human monocytes and adhesion to endothelial cells

  1. NanLing Gong,
  2. Heming Wei*,
  3. Sanaul Haq Chowdhury*, and
  4. Subroto Chatterjee
  1. Johns Hopkins Singapore–National Heart Centre Vascular Biology Program, 41 Singapore Science Park II, Singapore 117610
  1. Communicated by Sen-Itiroh Hakomori, Pacific Northwest Research Institute, Seattle, WA, February 9, 2004 (received for review August 19, 2003)

Abstract

Despite the importance of platelet/endothelial cell adhesion molecule-1 (PECAM-1, CD31) in the adhesion and diapedesis of monocytes/lymphocytes, little is known about the mechanisms by which it is regulated. We explored the role of a glycosphingolipid, lactosylceramide (LacCer), in modulating PECAM-1 expression and cell adhesion in human monocytes. We observed that LacCer specifically exerted a time-dependent increase in PECAM-1 expression in U-937 cells. Maximal increase in PECAM-1 protein occurred after incubation with LacCer for 60 min. LacCer activated PKCα and -ε by translocating them from cytosol to membrane. This was accompanied by the activation of phospholipase A2 (PLA2) and the increase of cell adhesion, which were abrogated by chelerythrine chloride, 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide and 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (GÖ 6976) (PKC inhibitors). Similarly, bromoenol lactone (a Ca2+-independent PLA2 inhibitor) and methyl arachidonyl fluorophosphonate (an inhibitor of cytosolic PLA2 and Ca2+-independent PLA2) inhibited LacCer-induced PLA2 activity. Bromophenacyl bromide (a PLA2 inhibitor) abrogated LacCer-induced PECAM-1 expression, and this was bypassed by arachidonic acid. Furthermore, the arachidonate-induced up-regulation of PECAM-1 was abrogated by indomethacin [a cyclooxygenase (COX)-1 and -2 inhibitor] or N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide (a COX-2 inhibitor) but not nordihydroguaiaretic acid (a lipoxygenase inhibitor). In sum, PKCα/ε are the primary targets for the activation of LacCer. Downstream activation of intracellular Ca2+-independent PLA2 and/or cytosolic PLA2 results in the production of arachidonic acid, which in turn serves as a precursor for prostaglandins that subsequently stimulate PECAM-1 expression and cell adhesion. These findings may be relevant in explaining the role of LacCer in the regulation of PECAM-1 and related pathophysiology.

Footnotes

  • To whom correspondence should be addressed. E-mail: schatte2{at}jhmi.edu.

  • * H.W. and S.H.C. contributed equally to this work.

  • Abbreviations: HUVEC, human umbilical vein endothelial cell; iPLA2, intracellular Ca2+-independent phospholipase A2; cPLA2, cytosolic PLA2; BPB, bromophenacyl bromide; GÖ 6850, 2-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)-maleimide; GÖ 6976, 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole; COX, cyclooxygenase; Lacer, lactosylceramide; PECAM-1, platelet/endothelial cell adhesion molecule-1; ICAM-1, intercellular cell adhesion molecule-1.

« Previous | Next Article »Table of Contents